NGAM Advisors L.P. reduced its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 1.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,402 shares of the medical instruments supplier’s stock after selling 148 shares during the period. NGAM Advisors L.P.’s holdings in West Pharmaceutical Services were worth $983,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Burt Wealth Advisors raised its stake in West Pharmaceutical Services by 38,540.0% in the first quarter. Burt Wealth Advisors now owns 1,932 shares of the medical instruments supplier’s stock worth $158,000 after buying an additional 1,927 shares in the last quarter. Harfst & Associates Inc. bought a new stake in West Pharmaceutical Services during the first quarter worth about $186,000. Tyers Asset Management LLC raised its stake in West Pharmaceutical Services by 17.6% in the first quarter. Tyers Asset Management LLC now owns 2,464 shares of the medical instruments supplier’s stock worth $201,000 after buying an additional 368 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in West Pharmaceutical Services by 1.6% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 2,569 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 40 shares in the last quarter. Finally, Koch Industries Inc. bought a new stake in West Pharmaceutical Services during the first quarter worth about $225,000. 90.51% of the stock is currently owned by institutional investors.

Shares of West Pharmaceutical Services, Inc. (NYSE:WST) opened at 85.99 on Thursday. The firm has a market cap of $6.36 billion, a price-to-earnings ratio of 36.91 and a beta of 1.10. The stock’s 50 day moving average price is $91.02 and its 200 day moving average price is $88.86. West Pharmaceutical Services, Inc. has a 12 month low of $70.17 and a 12 month high of $99.91.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The company had revenue of $397.60 million during the quarter, compared to the consensus estimate of $406 million. During the same quarter in the prior year, the business earned $0.59 earnings per share. The company’s revenue was up 2.5% compared to the same quarter last year. Equities research analysts predict that West Pharmaceutical Services, Inc. will post $2.69 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Wednesday, October 18th will be paid a $0.14 dividend. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.13. The ex-dividend date is Tuesday, October 17th. This represents a $0.56 annualized dividend and a dividend yield of 0.65%. West Pharmaceutical Services’s payout ratio is 22.22%.

WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/17/ngam-advisors-l-p-has-983000-position-in-west-pharmaceutical-services-inc-wst.html.

WST has been the topic of a number of analyst reports. Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research report on Friday, June 23rd. BidaskClub lowered West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $90.00 price target on shares of West Pharmaceutical Services in a research report on Thursday, June 8th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. West Pharmaceutical Services presently has a consensus rating of “Hold” and a consensus price target of $90.18.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Stock Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related stocks with our FREE daily email newsletter.